Depression & Neuroplasticity

Research links depression to changes in synaptic function, stress signalling and brain networks, and several treatments affect plasticity in laboratory models. But depression is biological, psychological and social at once, most cellular evidence comes from animals, and no plasticity measurement can diagnose depression or predict who will respond to treatment.

Depression and plasticity research: synaptic and neurotrophic theories, human imaging, and where mechanism stops and evidence begins.

Plasticity is one useful research framework for depression - not a complete explanation of it, and not a diagnosis.

Key takeaways

Why plasticity entered the depression conversation

For most of the twentieth century depression was framed around monoamine neurotransmitters. That framing did not explain why antidepressant effects on neurotransmitter levels are rapid while symptom change is slow, and it did not account for the role of chronic stress. [2] Researchers therefore began asking whether the relevant changes were not in the amount of a chemical but in how connections between neurons adapt over weeks. [3]

This is the plasticity framework: the proposal that depression involves altered capacity of circuits, particularly in prefrontal and hippocampal regions, to reorganise in response to experience, and that recovery involves restoring that capacity. [4] It is a productive hypothesis. It is not an established cause, and depression research today treats it as one dimension alongside inflammation, circadian biology, cognition, early adversity, and current social circumstances. [1]

What this article is not: This page explains how neuroplasticity research relates to depression. It is not a symptom checklist, a diagnostic tool, or treatment advice. If you are struggling, a qualified clinician is the right place to start.

Depression is not simply low neuroplasticity

Popular summaries sometimes compress the research into "depression is a plasticity deficit" or "depression is low BDNF." Neither is an accurate reading. Depression is defined clinically by symptoms and functional impact, and the same diagnosis covers people with very different biology, histories and circumstances. [1][2]

There is no test - imaging, blood or otherwise - that measures a person's neuroplasticity and returns a depression result. Where group differences exist, they are averages across large samples with substantial overlap between people with and without a diagnosis. [8] Treating plasticity as the definition of depression trades a complicated truth for a tidy story.

The synaptic and neurotrophic hypotheses

In rodent models, chronic stress reduces the number and function of synapses on prefrontal and hippocampal neurons, and several antidepressant treatments reverse that loss. [3] Related work proposes that neurotrophic signalling, including BDNF, supports the synaptic changes involved in recovery from stress. [3][11]

These findings are genuinely important, and they are animal findings, measured with methods that require brain tissue. The corresponding human work is indirect. An integrative model has argued the useful move is to connect these cellular ideas to measurable psychological processes in people - how flexibly attention, memory and expectation update - rather than treating cellular plasticity as if it had been observed directly in patients. [4]

Mechanism is not proof of benefit: A treatment that increases synaptic markers in a rodent model has not thereby been shown to help people. Clinical benefit is established by trials in patients, not by mechanism. [3][6]

Antidepressants, plasticity, and what the clinical evidence actually says

A large network meta-analysis of 21 antidepressants in adults with major depression found all were more effective than placebo on average in short-term treatment, with modest effect sizes and meaningful differences between drugs in efficacy and acceptability. [6] That is the clinical picture: real average benefit, wide individual variation, and no basis for predicting a specific person's response.

Separately, a systematic umbrella review of the serotonin literature concluded there is no consistent evidence that depression is caused by low serotonin or reduced serotonin activity. [5] Read precisely, that challenges the simple serotonin-deficiency or "chemical imbalance" hypothesis as a comprehensive causal explanation. It does not show that serotonin signalling is uninvolved in depression or in antidepressant pharmacology, and it says nothing about whether the drugs work - a network meta-analysis of antidepressant trials found they were more effective than placebo for adults with major depression. [5][6] Efficacy and mechanism are different questions. It does mean the "chemical imbalance" explanation was never well supported, and that the plasticity framework should not become its replacement slogan.

BDNF, blood tests and the limits of biomarkers

A meta-analysis of 179 associations found serum BDNF concentrations were, on average, lower in people with depression and higher after antidepressant treatment, but with considerable heterogeneity and evidence of publication and measurement effects. [7] The authors treated the finding as a weak peripheral signal rather than a clinical marker.

The deeper problem is interpretive, and it is the same one covered in our BDNF article: peripheral blood BDNF is not a validated proxy for BDNF activity in the living human brain. [7] A blood result cannot confirm or exclude depression, cannot show that a treatment has changed brain plasticity, and should not be marketed as either.

Brain imaging: real group differences, no individual diagnosis

Large-scale coordinated analyses across many international samples have found subtle subcortical differences associated with major depression, including modest hippocampal volume differences that were more pronounced in people with recurrent or early-onset illness. [8] These are small average effects in samples of thousands.

Two cautions follow. First, cross-sectional differences cannot establish direction: they do not show that depression shrank a structure, nor that a structural feature caused depression. Second, an average difference across thousands of people says nothing reliable about any single scan. Imaging is a research tool here, not a clinical test. [8]

Adult neurogenesis: an unresolved dispute

The idea that antidepressants work by promoting the birth of new hippocampal neurons is widely repeated. In humans, whether meaningful adult hippocampal neurogenesis occurs at all remains disputed: one 2018 study reported that it persists throughout ageing, and another published the same year reported it drops to undetectable levels in adults. [9][10] The disagreement is methodological and has not been settled.

Given that, adult neurogenesis is a poor foundation for claims about how depression treatments work in people. It remains an open scientific question rather than an explanation.

Does untreated depression damage the brain?

Some findings show larger imaging differences in people with more depressive episodes, and animal work shows chronic stress remodels hippocampal and prefrontal circuits. [8][11] This has been popularised into the claim that untreated depression permanently damages the brain. That claim goes well beyond the evidence.

In the animal work, several stress-related structural changes are reversible once the stressor ends. [11] In human studies, the associations are correlational and could reflect illness burden, medication, sleep, activity, or shared vulnerability. Framing depression as accumulating irreversible brain damage adds fear without adding accuracy - and fear is not a good reason to seek care. Wanting to feel better is reason enough.

What we know

What we are still learning

Practical implications

Cautions

Frequently asked questions

Is depression caused by low neuroplasticity?

No established evidence shows that. Reduced plasticity is one hypothesis, developed mainly in animal models, and it sits alongside psychological, social, inflammatory and circadian contributors. Depression is not defined or diagnosed by a plasticity measurement.

Do antidepressants work by increasing neuroplasticity?

Several antidepressant treatments increase markers of synaptic plasticity in animal models, which is where that idea comes from. Whether this is the mechanism of clinical benefit in people is not established, and clinical effectiveness is assessed separately in trials.

Can a BDNF blood test tell me about my depression?

No. Average serum BDNF differences reported in depression are small and inconsistent, and blood BDNF is not a validated proxy for BDNF activity in the living human brain. It is not a diagnostic or monitoring test.

Does untreated depression permanently damage the brain?

That claim is not supported. Some imaging associations exist with recurrent illness, and animal stress research shows remodelling that is often reversible when the stressor ends. Correlational human findings cannot establish permanent damage.

Can therapy change the brain?

All learning involves brain change, and psychological therapy is a form of structured learning, so change is expected in principle. What imaging can currently show is limited and group-level, so it is better to judge therapy by whether it helps a person function and feel better.

Related on Beiing

Sources

  1. Depression - Malhi GS, Mann JJ, The Lancet, 2018
  2. The molecular neurobiology of depression - Krishnan V, Nestler EJ, Nature, 2008
  3. Synaptic dysfunction in depression: potential therapeutic targets - Duman RS, Aghajanian GK, Science, 2012
  4. Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model - Price RB, Duman R, Molecular Psychiatry, 2020
  5. The serotonin theory of depression: a systematic umbrella review of the evidence - Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA, Molecular Psychiatry, 2023
  6. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis - Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, et al., The Lancet, 2018
  7. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N = 9484) - Molendijk ML, Spinhoven P, Polak M, Bus BAA, Penninx BWJH, Elzinga BM, Molecular Psychiatry, 2014
  8. Subcortical brain alterations in major depressive disorder: findings from the ENIGMA Major Depressive Disorder working group - Schmaal L, Veltman DJ, van Erp TGM, Sämann PG, Frodl T, et al., Molecular Psychiatry, 2016
  9. Human hippocampal neurogenesis persists throughout aging - Boldrini M, Fulmore CA, Tartt AN, et al., Cell Stem Cell, 2018
  10. Human hippocampal neurogenesis drops sharply in children to undetectable levels in adults - Sorrells SF, Paredes MF, Cebrian-Silla A, et al., Nature, 2018
  11. The brain on stress: vulnerability and plasticity of the prefrontal cortex over the life course - McEwen BS, Morrison JH, Neuron, 2013

Published · Updated

Educational content only - not medical advice. In a crisis, call or text 988 (US) or your local emergency number. See crisis resources.